X
All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area: Immunology Product Name: Diregura
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: LTL Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
Details:
LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inolimomab
Therapeutic Area: Immunology Product Name: Leukotac
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2021
Details:
ElsaLys Biotech confirmed that The French National Agency for the Medicines and Health Products Safety (ANSM) has renewed the Temporary Authorisation for Use (ATU) so-called cohort ATU (cATU) for inolimomab (LEUKOTAC®) on December 24, 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inolimomab
Therapeutic Area: Immunology Product Name: Leukotac
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 19, 2021
Details:
The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery and two expert academic teams, has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2020
Details:
Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
